|
| 双重抗骨质疏松药雷尼酸锶 |
| Strontium ranelate: an anti-osteoporotic drug with dual effects |
| 投稿时间：2012-07-12 |
| DOI： |
| 中文关键词: 雷尼酸锶 骨质疏松 骨形成 骨吸收 |
| 英文关键词:Strontium ranelate Osteoporosis Bone formation Bone resorption |
| 基金项目: |
|
| 摘要点击次数: 1045 |
| 全文下载次数: 0 |
| 中文摘要: |
| 不同于其他抗骨质疏松药,雷尼酸锶是新型具有双重药理作用的抗骨质疏松药物,即抑制骨吸收和促进骨形成.雷尼酸锶可改变骨微结构,增加骨密度和骨强度,从而降低骨折风险,改善患者生活质量.临床研究显示,它能降低绝经后骨质疏松患者椎体和非椎体骨折的风险,并具有作用长久、安全性好、耐受性好的特点. |
| 英文摘要: |
| Unlike other anti-osteoporotic drugs, strontium ranelate (SR) is a novel anti-osteoporotic drug, which has unique dual effects on bone metabolism, including promoting bone resorption and inhibiting bone formation. SR can alter the bone microstructure, and increase the bone mineral density and bone strength. Thus, SR can reduce the risk of fractures and improve the life quality of the patients. Clinical researches reveal that SR can reduce the risk of vertebral and non-vertebral fractures in patients with postmenopausal osteoporosis. The effect of SR can maintain for a long time. The safety and tolerance of SR are good. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|